Tag Archives: Global

Global Bipolar Disorders Market to Reach $5.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

August 03, 2012     No comments

San Jose, California (Vocus) June 11, 2010

Bipolar disorder is a chronic and devastating psychiatric disease. Since neither curable nor effectively treatable, the bipolar disorder market is present with significant unmet medical needs. The major drawbacks of existing products include dyskinesis, obsessive-compulsive behavior and psychiatric side effects, as well as ineffectiveness in treating cognitive deficits, rapid recycling or depressive symptoms. In addition, though anti-convulsants (such as Valproic acid) and lithium have considerably enhanced disease prognosis, several patients show poor tolerance to treatment-related side effects. Other major clinical setbacks include lack of compliance to treatment regimen, inadequate clinical response, and relapse.

The United States dominates the world bipolar disorder market as stated by the new market research report on bipolar disorder market. According to the U.S. National Institute of Mental Health, there are about 5.7 million adults aged 18 years and over, suffering from bipolar disorder in the US. The treatment of bipolar disorder differs based on physician specialty in the country. Most psychiatrists follow the recommendations of the American Psychological Association and prescribe lithium, valproic acid and atypical antipsychotics as first-line monotherapies for bipolar mania, and Lamictal as the recommended treatment for bipolar depression. And, unlike the psychiatrists who follow the APA guidelines and prescribe Lamictal first-line, primary care physicians select antidepressants first line.

Bipolar disorder is highly consolidated marketplace with the leading five players accounting for the lion?s share of the market. These players are unlikely to face any major challenge(s) in the future, as pipeline molecules are all targeted at providing only symptomatic relief, and no company is developing any therapy that promises a paradigm shift in the treatment of bipolar disorder. Key players profiled in the report include Abbott Laboratories Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon Inc., Dainippon Sumitomo Pharma Co. Ltd., Eli Lilly and Company, Forest Laboratories Inc., Gedeon Richter PLC, GlaxoSmithKline PLC, H. Lundbeck A/S, Janssen Pharmaceutica Inc., Merck & Co., Inc., Otsuka America Pharmaceutical Inc., Pfizer Inc., Repligen Corporation, and Validus Pharmaceuticals Inc.

The report titled ?Bipolar Disorders: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a review of unmet medical needs, opportunities and challenges, patent expiries, competitive scenario, select leading products, select pipeline drugs, clinical trials, product approvals/launches, recent industry activity, and coverage on major global market participants. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe, Asia-Pacific and Rest of World. Global market is analyzed by the following drug classes – Atypical Anti-psychotics and Other Therapeutics.

For more details about this market research report, please visit ?

http://www.strategyr.com/Bipolar_Disorders_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Email press(at)StrategyR(dot)com

Web Site http://www.StrategyR.com/

###







Read More

ATMOS Global Revolutionary ?Air Quality and Climate Change Academy? Launches Globally

July 31, 2012     No comments


Melbourne, Australia (PRWEB) July 31, 2012

ATMOS Global ? (ATMOS Australia Pty Ltd ? Elite Atmospheric Air Quality Modelling & Forecasting and Climate Change Research Consultants ?) launches globally its revolutionary Air Quality and Climate Change Academy ? a highly specialized and workplace specific air quality and climate change training and learning portal that offers ATMOS Global?s industrial clients, with operations located anywhere in the world, an opportunity to keep up to date with leading edge concepts and practices associated with addressing air quality management, dust management and climate change related challenges important to the mining, manufacturing and energy industries.

The radical transformation of the world and current workplace diversity and mobility trends have led to an increased demand for ?learning by doing? training services that meet the learners? needs for flexibility by providing direct access to information relevant to their work environment when they need it in real life situations.

Dr Orestis Valianatos, the Global President and Chief Executive Officer of ATMOS Global, said that ?ATMOS Global?s Air Quality and Climate Change Academy ? aims to be a leader in the Digital Education Revolution, a new concept of learning that helps our clients deal with the current far-reaching changes in our economic and technological landscapes. It shifts the learning and development paradigm to a performance improvement process?.

?While responding to our clients? need for profound practical understanding of the key contemporary air quality management, dust management and climate change challenges surrounding their operations, ATMOS Global?s Air Quality and Climate Change Academy also opens the door to an optimal learning structure that closes the learning-doing gap by providing our clients with a hands-on approach to understanding and mastering the use of ATMOS Global?s world?s first advanced air quality management and dust management platforms ATMOS-5D ?, ATMOS-5D+ ?, DustAlert ? and DustAlert+ ? that operate in the forecasting service framework provided by ATMOS Global?s Center for Global and Site Specific Dust Impact Forecasting, Management and Control ?? he said.

The Air Quality and Climate Change Academy is an ?add-on? to ATMOS Global?s elite air quality management, air quality forecasting, dust management, dust impact forecasting? and climate change services. ATMOS Global?s Air Quality and Climate Change Academy is an innovative instructional platform for delivering information and knowledge using an expert training architecture that integrates formal and informal learning and uses the best process and technology to deliver timely and engaging learning solutions and provide real-time answers to employees? work-related enquiries.

ATMOS Global?s Air Quality and Climate Change Academy ? innovative workplace training services have been used for a mining project nominated as a finalist (jointly with ATMOS Australia/ATMOS Global) for one of the most prestigious awards for environmental excellence in Australia.

Prospective client companies with active/proposed mining, manufacturing or energy operations that are interested in learning more about ATMOS Global?s Air Quality and Climate Change Academy ? are invited to contact our friendly ATMOS Global?s Air Quality and Climate Change Ambassadors ? for further information and a confidential phone consultation by visiting our new website http://www.atmosglobal.com.

Notes for editors

Dr Orestis Valianatos is the Global President and CEO of ATMOS Global (ATMOS Australia Pty Ltd). He has extensive experience and an influential global perspective in the fields of atmospheric and air quality forecasting (model/system developer and user), education and strategic corporate advisory services. Entrepreneur and agent of change, he has authored more than 50 ground breaking air quality research publications (internationally published). In 1999, Dr Valianatos initiated an ongoing successful journey to pioneer, encourage and support the use of advanced 3D dispersion modelling, numerical weather prediction and air quality forecasting concepts and techniques for the day to day understanding and management of complex air quality issues for the mining, manufacturing and energy industries.

ATMOS Global (ATMOS Australia Pty Ltd) is a wholly Australian owned leading global strategic consulting company specialising in the provision of advanced innovative atmospheric, air quality modelling & forecasting and climate change services. We have been developing and pioneering advanced three dimensional (3D) Numerical Weather Prediction and complex air quality modelling & forecasting tools to deliver accurate air quality management solutions for the mining, manufacturing and energy industries for almost two decades.

For further information please contact:

Dr Orestis Valianatos

Global President and Chief Executive Officer

ATMOS Global ? (ATMOS Australia Pty Ltd)

Phone: +61-1300-69-28667 (+61-1300-MY-ATMOS)

Email: orestis(at)atmosglobal(dot)com

http://www.atmosglobal.com







More ADD Press Releases

Read More

MeCP2 Goes Global ? Redefining the Function of the Rett Syndrome Protein

July 27, 2012     No comments


Trumbull, CT (PRWEB) February 26, 2010

A paper published online today in Molecular Cell proposes that Methyl CpG binding protein 2 (MeCP2) impacts the entire genome in neurons, rather than acting as a regulator of specific genes. Mutations in MeCP2 cause the autism spectrum disorder Rett Syndrome as well as some cases of neuropsychiatric problems including autism, schizophrenia and learning disabilities.

The discovery of MeCP2?s global reach was made in the laboratory of Adrian Bird, Ph.D. of the University of Edinburgh. Bird?s seminal contributions in the Rett Syndrome field include cloning the MeCP2 protein in the early 1990?s and the dramatic reversal of severe symptoms in fully mature mice models of the disease published in Science in 2007. He is a Trustee and Scientific Advisor of the Rett Syndrome Research Trust, a nonprofit organization intensively focused on the development of treatments and cures for Rett Syndrome and related MECP2 disorders.

Rett Syndrome strikes little girls almost exclusively, with first symptoms usually appearing before the age of 18 months. These children lose speech, motor control and functional hand use, and many suffer from seizures, orthopedic and severe digestive problems, breathing and other autonomic impairments. Most live into adulthood, and require total, round-the-clock care.

Historically, MeCP2 has been viewed as a classic transcription factor, but Bird?s data establishes MeCP2 as one of the most abundant neuronal nuclear proteins, with levels 100 to 1,000 times higher than typical transcription factors. In fact, there are nearly as many molecules of MeCP2 in the nucleus as there are nucleosomes, the fundamental repeating structural units of chromatin which in turn make up chromosomes. To put this in perspective, there is enough MeCP2 to cover nearly the entire genome.

Peter Skene, a post-doctoral fellow in the Bird lab and first author of the paper confirmed via chromatin immunoprecipitation and high throughput sequencing that this huge abundance of MeCP2 meticulously tracks the DNA methylation pattern of the cell. As a result, Skene observed that most regions of the genome bind to MeCP2, calling into question the previously assigned role of this protein as a target-specific transcription factor. This may explain why few clear gene targets for MeCP2 have been identified in the last decade.

?The brain contains many types of neurons with different functions, but interestingly it appears that the pattern of MeCP2 binding to chromosomes is broadly similar in all of them. This raises the possibility that the neuronal defect brought about by mutations in this gene affect all neurons in a similar way. If there really is a generic defect shared by many neurons, then the causes of Rett Syndrome may be less complicated than we feared. This idea now needs to be tested by further work,? said Professor Bird.

In line with its genome-wide distribution, the scientists found that MeCP2 globally impacts the packaging of the DNA in the cell. Histones are proteins which act as spools around which DNA is wound. This winding, or compaction, allows the 1.8 meters of DNA material to fit inside each of our cells. There are two classes of histones ? core histones and linker histones. Core histones form the spool around which DNA winds – resembling beads on a string. The linker histones, such as histone H1, seal the DNA onto the spool formed by the core histones. In this way linker histones act as a padlock to hold the DNA in this structure and stop inappropriate access to the DNA outside of genes. In the absence of MeCP2, the amount of linker histone H1 doubles, suggesting an attempt to compensate for the lack of MeCP2.

The Bird lab also found an increase in histone acetylation in MeCP2-deficient neurons, but not in glia. These chemical modifications lead to an unwinding of the chromatin spools and potentially leave the DNA open for inappropriate expression. This suggests that the role of MeCP2 is to globally suppress the genome.

?Consistent with MeCP2 coating the entire genome, we observed global changes in the chromatin composition and activity. In the absence of MeCP2, we discovered an increase in the spurious transcription of the so-called ?junk DNA? which lies between genes. This suggests to us that rather than targeting specific genes, MeCP2 functions on a genome-wide level and may act as the watchdog of the neuronal genome,? said Skene.

?RSRT is pursuing two parallel approaches to interventions for Rett Syndrome. One is to find assays for MeCP2 function and then screen for anything that fixes the defect. The other is to understand as much as possible about what MeCP2 does in the brain and then design rational treatments. Understanding that MeCP2 acts in a global manner rather than as a gene-specific regulator gives us a new perspective on the molecular basis of Rett Syndrome that will aid in guiding drug development and other treatment modalities,? comments Monica Coenraads, Executive Director of RSRT and parent of a child with the disorder.

For an in-depth interview with Adrian Bird please visit the RSRT Blog, http://rettsyndrome.wordpress.com/

About Rett Syndrome Research Trust

The Rett Syndrome Research Trust is a nonprofit research organization formed in the wake of the dramatic pre-clinical reversal of Rett Syndrome symptoms. The Trust is intensively focused on the development of treatments and cures for Rett Syndrome and related MECP2 disorders. Our short-term goal is to deliver clinical trials of a novel treatment strategy within five years. The strength of the Trust is based on the guidance of advisors who are largely responsible for the major advances in Rett research over the past decade. To learn more about the Trust please visit http://www.reverserett.org

# # #







Find More Schizophrenia Press Releases

Read More

Global Irritable Bowel Syndrome (IBS) Therapeutics Market to Reach $1.47 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

July 24, 2012     No comments

(PRWEB) August 25, 2011

San Jose, California (PRWEB), August 25, 2011 — Irritable Bowel Syndrome, a recurring Gastrointestinal illness, represents an under-penetrated market with a large number of generic drugs presently in use for treating the multiple symptoms. Owing to lack of proper understanding of the disease etiology, the causes, and misdiagnosis of symptoms, only countable number of drugs is presently available in the market for treating more than one symptom associated with IBS. However, over the years, the market has witnessed several improvements, such as the establishment of well-defined diagnostic criteria, exploring novel therapeutic drug classes, emergence of alternative medicines and therapies, in addition to the growing awareness about the chronic nature of the disease.

The global market for Irritable Bowel Syndrome (IBS) therapeutics is presently underserved with a high degree of fragmentation due to the non-availability of a single drug for treating all symptoms associated with this chronic illness. Further, upon considering the diagnostic scenario, nearly 70% of the cases remain undiagnosed while the disease prevalence is quite high. During the initial onset of the disease, patients prefer self-medication based upon their symptoms and rely upon OTC products. The prescription market for IBS comprises of a very few approved drugs for addressing more than one symptom, which show only sub optimal efficacy, and in some cases result in adverse side effects. Physicians prescribe multiple drugs that are not adequate for subsiding the pain, discomfort, and other IBS symptoms. The approval and subsequent release of safe and effective medicines for IBS treatment in the near future is expected to result in substantial growth of the IBS market owing to the premium pricing of these drugs upon release.

The US represents the largest market for irritable bowel syndrome (IBS) therapeutics worldwide, as stated by the new market research report on Irritable Bowel Syndrome Therapeutics. Europe represents the second largest market for IBS therapeutics. Rest of World is projected to emerge as the fastest growing market for IBS therapeutics, exhibiting a CAGR of more than 12% over the analysis period.

The high prevalence and anticipated launch of new drugs in the developed markets during and post 2012 is expected to drive the growth of the IBS market in the coming years. Lotronex (2000) and Amitiza (2008) are the only drugs presently approved for the treatment of Diarrhea Predominant IBS (IBS-D) and Constipation Predominant IBS (IBS-C), respectively. Post US FDA approval and market release in February 2000, Lotronex was withdrawn from the US market in December 2000 owing to safety concerns over this drug. Lotronex was re-launched in 2005, although with a warning label, for restricted use in patients in whom the risk to benefit ratio is balanced. The re-launch of the drug despite the risk associated with its use reflects the high unmet need existing in the IBS therapeutics market. Amitiza, approved for the treatment of IBS-C, is associated with adverse events and side effects. The drug?s safety profile limits the drug?s market size despite its efficacy.

The late stage drug pipeline of Irritable Bowel Syndrome comprises of drug candidates with novel mechanisms of action, and do not belong to the 5HT class of drugs which dominated the drug-development pipeline for the past several years. Despite the efficacy, 5HT class of drugs lack gut-selectivity acting on receptors present in the gut as well as the brain, which is the primary reason for the side effects associated with their use. New drugs in the late stage IBS pipeline, including Linaclotide, Asimadoline, and Dexloxiglumide, exhibit novel modes of action and have demonstrated positive results in terms of safety and efficacy in their respective late stage clinical trials, which makes them promising candidates in the field of IBS treatment. Moreover, each of these is found to be effective in treating a particular IBS-subtype, and not just a single symptom associated with IBS, in respective clinical studies.

Major players profiled in the report include Abbott Laboratories, Edusa Pharmaceuticals, Ironwood Pharmaceuticals Inc., Forest Laboratories Inc., Lexicon Pharmaceuticals, Ocera Therapeutics Inc., Pharmos Corporation, Sucampo Pharmaceuticals Inc., Tioga Pharmaceuticals Inc., among others.

The research report titled ?Irritable Bowel Syndrome (IBS) Therapeutics: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the Irritable Bowel Syndrome (IBS) market, the disease prevalence, classification, causes, diagnosis, current treatment scenario, select treatments and therapies along with side effects, product approvals in the past, clinical trials, early and late stage pipeline, recent industry activity, product innovations, and profiles of major/niche global market participants. The report provides annual value sales estimates and projections for Irritable Bowel Syndrome Therapeutics market for the years 2009 through 2017 for the following geographic regions ? US, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Irritable_Bowel_Syndrome_IBS_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







More Early Onset Press Releases

Read More

Fator Securities Selects SunGard for Trade Management and Global Connectivity

July 23, 2012     No comments

New York, NY (PRWEB) January 23, 2012

Fator Securities LLC, a U.S. broker-dealer serving as the U.S. distribution arm of the Fator group of companies in Brazil, has selected SunGard?s Valdi Order Management System (OMS) for trade management and SunGard Global Network (SGN) for global connectivity.

Fator Securities provides asset managers, broker-dealers and other investment professionals with brokerage and trading solutions as well as electronic market access to Latin American exchanges. SunGard?s solutions will help Fator Securities manage trade execution, trade automation and connectivity to more than 120 markets and 500 brokers worldwide. Using solutions from a single provider will help Fator Securities decrease its technology costs, increase operational efficiencies and access new sources of liquidity.

Valdi OMS provides a consolidated view of trading activity with access to global markets and multiple asset classes. It will help Fator Securities expand its business by helping it monitor positions and manage risk around the world on one screen. The SunGard Global Network (SGN) provides financial institutions with global connectivity to equities and derivatives exchanges around the world.

Erminio Lucci, head of sales and trading for Fator Securities, said, ?We selected SunGard to help us automate workflow, lower costs and increase revenue through the ability to source new liquidity through SGN. By using SunGard for order management and global connectivity we can rely on one strategic vendor partner to help us grow our business.?

Philippe Carr?, global head of connectivity for SunGard?s capital markets business, said, ?SunGard will help Fator Securities trade more efficiently in the United States and in Latin America by providing low latency connectivity and order and execution management from one screen.?

About Fator Securities

Fator Securities LLC, Member FINRA/SIPC, is a U.S. entity and a subsidiary of the Fator group of companies in Brazil. Fator Securities is located in New York, New York and offers institutional investors access to the Brazilian and other LatAm equities markets. Fator Securities and the SunGard companies are not affiliated. U.S persons seeking information regarding securities investments in Latin America should contact Fator Securities at (646) 205-1160.

About SunGard’s Valdi

SunGard?s Valdi provides equities, futures, fixed income and options traders with multi-asset trading solutions on 170+ markets worldwide. Valdi global trading solutions support the entire trade lifecycle, including integrated trade and order management systems, execution services, market data, risk management, compliance, and clearing and settlement services. Also offering worldwide connectivity via the SunGard Global Network (SGN), SunGard’s Valdi global trading solutions help customers to achieve increased performance and low latency execution across multiple platforms, instruments and geographies.

About the SunGard Global Network (SGN)

A trade automation and connectivity solution, the SunGard Global Network links institutions throughout the financial services value chain, offering services for equities, fixed income, listed derivatives, mutual funds, money market funds and other cash equivalents. SGN helps automate the entire trade lifecycle, from order execution through to post-trade processing. It facilitates trading on over 120 markets worldwide and links more than 2,000 asset managers with over 500 brokers, as well as interconnecting with major third-party order-routing networks. SGN?s international connectivity hubs also support low-latency market data delivery from global markets.

About SunGard

SunGard is one of the world?s leading software and technology services companies. SunGard has more than 17,000 employees and serves approximately 25,000 customers in more than 70 countries. SunGard provides software and processing solutions for financial services, education and the public sector. SunGard also provides disaster recovery services, managed IT services, information availability consulting services and business continuity management software. With annual revenue of about $ 4.5 billion, SunGard is the largest privately held software and services company and was ranked 434 on the Fortune 500 in 2011. Look for us wherever the mission is critical. For more information, please visit http://www.sungard.com.

Trademark Information: SunGard, the SunGard logo, SunGard Global Network and Valdi are trademarks or registered trademarks of SunGard Data Systems Inc. or its subsidiaries in the U.S. and other countries. All other trade names are trademarks or registered trademarks of their respective holders.

SGN Brokerage Services offered in the United States are provided by SunGard Institutional Brokerage Inc., Member FINRA / SIPC.

SGN Brokerage Services offered throughout Europe, the Middle East, Africa and Asia Pacific are provided by SunGard Global Execution Services Limited which is authorised and regulated by the Financial Services Authority, No. 469919 . Incorporated and registered in England and Wales No. 3127109 . Registered Office: 25 Canada Square, London E14 5LQ.

###





Read More

Lingerie Site Announces ?50 Shades of Grey? Supporting Global Impact of ?Grey? Author?s Comic Con Frenzy

July 22, 2012     No comments


Houston, TX. (PRWEB) July 20, 2012

After best-selling author, E.L. James, the creator of the cultural phenomenon ?50 Shades of Grey,? appeared at Comic Con last week to hoards of adoring fans, lingerie company Sparkling Strawberry announced a new line inspired by the erotic novel. According to reports, the author?s Comic Con appearance featured hundreds of fans who not only wanted autographs but to speak to James about the impact the world-famous novel has had on their sex lives.

With the ?50 Shades of Grey? series already selling more than 20 million copies there is no denying the cultural impact this book has had on the world and on many couples. Inspired by the frenzy caused at Comic Con and the apparent impact James and her novel have had on people?s sex lives, Sparkling Strawberry decided to create their own homage to the novel. Now female fans of the wildly popular erotic love story can adorn, ?50 Shades of Lingerie,? a fantasy-inspired line of lingerie inspired by the book series.

The company hopes that the millions of women who have been inspired by the novel and who credit the author with revamping their sex lives while giving them additional confidence, will turn to the lingerie line to continue to embrace this part of their lives. The line was created specifically for women who want to add the same type of excitement to their lives that the ?50 Shades of Grey? series has. The new line has launched on the company?s website at sparklingstrawberry.com and is now available for purchase.

For more information on the new ?50 Shades of Lingerie? offer and for more information on the entire Sparkling Strawberry line of lingerie, visit http://www.sparklingstrawberry.com/categories/Sexy-Lingerie/Fifty-Shades-of-Lingerie/.







Read More

Global ADME-Toxicology Testing Market to Exceed $10 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

July 21, 2012     No comments

San Jose, California (PRWEB) August 29, 2011

New drug discovery is increasingly becoming a high cost proposition for pharmaceutical and biotech companies, owing particularly to the high attrition rate due to drug failure at different stages. Development of a new drug costs about $ 1.0 billion and takes, on an average, 7-10 years before reaching commercialization stage. With companies facing major revenue losses owing to patent expirations and demanding regulatory requirements, besides growing cost pressures, there is growing need to reduce fixed costs and adopt flexible cost models. ADME-Tox issues comprise a leading cause for drug failure/attrition during the pre-clinical as well as clinical stage. The increasing number of drug targets and volume of assay points in drug discovery process are necessitating the need for identifying and eliminating potential hits with high ADME and toxicity profiles. Hence ADME/Tox screening has now become essential at early stage drug discovery and development process. In addition, rising drug discovery costs are fostering the adoption of extensive ADME-Tox screenings not only at early stage of drug discovery and development process but also through the entire process.

Pharma companies are focusing efforts on various innovative approaches to enhance and accelerate ADME-Tox assessments. In silico predictive ADME-Tox is growing at a fast clip and is expected to gain further momentum as the technology can drastically reduce the expenditure incurred due to late stage failure of drug compounds owing to poor ADME-Tox properties. The use of computational models in prediction of ADME/Toxicity properties of compounds is also increasing at a rapid rate owing to the fact that these models offer significant benefits in high throughput screening (HTS). Owing to the significant role of transporter proteins, analysis of drug transporters is gradually becoming a part of ADME assessment and is likely to become a part of regulatory standard for new drug applications.

The United States and Europe account for a lion?s share of the global ADME-Toxicology testing market, as stated by the new market research report on ADME-Toxicology Testing. With the US being home to most of the global pharmaceutical giants, the nation corners a major share of new drug discoveries across the world. The US market for In-Vivo Toxicology testing is forecast to exceed US$ 1.0 billion by 2015. Cell-based assays are expected to emerge as a vital technology in in-vitro test methods in toxicity testing, given their role either as a part of a tiered testing scheme or as test batteries in predicting human toxicity endpoints. Growing interest in screening new drug candidates has propelled the manufacturers of cell-based assays to provide reliable and robust solutions for drug discovery. High Throughput/High Content (HTS/HCS) cell-based assays enable the evaluation of several toxicity endpoints, which is expected to enable identification of various aspects associated with the onset of cell stress. This, in turn, aids in predicting specific cytotoxic effects.

While the US is expected to continue its dominant position in global market, developing regions including Asia-Pacific are poised to register the fastest growth. The high growth in these markets is buoyed by government support and increasing number of collaborations between foreign pharma companies and research laboratories in the region. In particular, India and China have rapidly emerged as ?hot spot? for R&D investment. The emergence and success of contract research organizations (CROs) has made outsourcing of various research projects related to new drug development a viable alternative for pharmaceutical companies, particularly for mid-tier and small players with inadequate infrastructure. Increasing emphasis on early stage ADME-Tox screening and prediction during the last decade and a half has resulted in emergence of large number of dedicated ADME-Tox CROs.

ADME-Tox technologies market place includes pharmaceutical and biotech companies with their in-house research teams and contract research organizations (CROs) that provide ADME-Tox screening at contract. Select players profiled in the report include Accelrys, Inc., ACEA Biosciences, Inc., Agilent Technologies, Inc., Albany Molecular Research, Inc., BD Biosciences, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Caliper Life Sciences, Inc., Cambridge Cell Networks Ltd, CeeTox, Inc., Cellartis AB, Celsis International Ltd., Cyprotex PLC, Entelos, Inc., Life Technologies Corporation, Molecular Discovery Ltd., MultiCASE, Inc., Noray Bioinformatics S.L., Optivia Biotechnology, Inc., Promega Corporation, Taconic Farms, Inc., Thermo Fisher Scientific, Inc., Xceleron, Inc. among others.

The research report titled ?ADME-Toxicology Testing: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a strategic review of the drug discovery and development market, key market trends in ADME-Tox Technologies, recent product launches, strategic corporate initiatives, and profiles of key market participants. The report provides annual expenditure on ADME-Tox Technologies by the following geographic markets – US, Canada, Japan, Europe and Rest of World. Segments analyzed include Toxicology (In-Vivo and In-Vitro) and ADME.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/ADME_Toxicology_Testing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







Read More

Placecast Hires Seasoned Mobile Executive Cameron Franks to Head Global Operator Sales

July 17, 2012     No comments


San Francisco, CA (PRWEB) September 30, 2011

Franks will lead expansion into new territories across Europe, Latin America and Asia.

To meet demand from global carriers interested in location-based marketing and offer management programs, Placecast has hired seasoned executive Cameron Franks to fill a newly-created position, Vice President of Operator Sales. With today?s hire Placecast plans to expand its award-winning mobile marketing platform further into Europe and into new regions such as Latin America and Asia.

An early member of Sybase365 (formerly Mobile 365 / Mobileway), Franks developed relationships with the largest mobile operators in the world, in roles based in the UK, Australia and the US. He served latterly as AVP of the Americas sales team, where he was responsible for driving sales and strategy with both Operators and Enterprises. In his eleven years at Sybase, Franks played an instrumental role in establishing the company as one of the leading players in mobile messaging and mobile commerce.

?I am excited about joining Placecast. The company?s ShopAlerts product has already demonstrated that it can open up a new source of advertising revenue for operators and reduce churn. With a portfolio of proven products and services for operators, Placecast has all the ingredients for explosive growth,? says Franks.

Placecast? ShopAlerts platform has proven successful due to the reach and simplicity of opt-in SMS/MMS mobile marketing. AT&T and Telefonica UK were among the first to license ShopAlerts to offer location-based mobile marketing to their subscribers. Telefonica UK?s You Are Here program now has over 6M opted-in subscribers.

?We are delighted to have Cameron on board with us. He brings a thorough understanding of operator technology deployment, key global relationships and an excellent track record. His appointment signals a new chapter of growth for Placecast as we scale worldwide,? stated Alistair Goodman, CEO of Placecast.

About Placecast

Placecast is the first location-based platform specifically designed to use mobile marketing to drive consumers into physical environments. Comprised of a team of experts in digital marketing, mobile solutions and location technology, Placecast offers ShopAlerts as a white-label offer management service for retailers and operators, and also licenses the Placecast Platform technology for the delivery of other types of location-based services. The ShopAlerts geofence marketing service has transformed the mobile industry: brands such as The North Face, L?Oreal, Starbucks and Chicos are all delivering location-based mobile offers to customers near their stores on any mobile phone. Operators deploy the company?s service to enroll subscribers in their location-based marketing program, opening new sources of revenue and reducing churn. The ShopAlerts service received significant recognition in 2010, taking home the prize for innovation given by the National Retail Federation as well as honorable mentions at the Mobile World Congress, Webby?s and CTIA. The company is backed by Quatrex Capital, ONSET Ventures and Voyager Capital.

###







Read More

Rising Incidence and High Relapse Rates Drive the Global Acute Myeloid Leukemia (AML) Therapeutics Market, According to New Report by Global Industry Analysts, Inc.

July 12, 2012     No comments

San Jose, CA (PRWEB) July 06, 2012

Follow us on LinkedIn ? Acute Myeloid Leukemia (AML) is identified as a rapidly progressing disease, associated with the elderly. Presently, approved drugs available for the treatment of AML include chemotherapy drugs such as cytarabine, anthracycline, daunorubicin, and mitoxantrone. These therapies, however, are marred with various negative factors such as low cure rates, major side effects such as neutropenia, and high relapse rates. Although other treatment options, such as bone marrow transplant offers comparatively better result, it is however not an effective option for most of the elderly patients due to its high toxicity and dearth of appropriate donors for the procedure. Therefore, the AML market is presently characterized by high unmet needs in terms of drug safety and efficacy presenting increased opportunities for new drugs with improved safety and efficacy profiles.

Over the years, the acute myeloid leukemia (AML) market has witnessed promising targeted drugs failing clinical trials, leading to the slowing down of growth prospects in the AML therapeutics scenario. Some of the promising targeted agents which have failed to improve outcomes in clinical trials include zosuquidar (P-glycoprotein modulator), sulfonylhydrazine alkylator laromustine, and Mylotarg (gemtuzumab ozogamicin). However, innovative new target agents are under various stages of clinical trials, which are expected to showcase promising results in the years to come. Also, AML therapeutic market, in recent years, has witnessed a surge in research and development activities centered on developing molecular targets, which target cell death (apoptosis) and cell cycling, apart from developing novel agents, which target DNA replication and repair. Other approaches which are being developed include immunotherapy and epigenetic based targeting. However, some of these approaches are still in their nascent stages of development, while others are exhibiting promising outcomes. In the upcoming years, the outcome of AML therapeutics are expected to be geared towards developing treatments which are less toxic and potentially safe for the elderly population, when compared to the traditional drugs.

One of the major drivers for the global AML market is the aging population worldwide. Since the incidence of AML significantly increases in the age group of 50 years and above, the aging population therefore forms a major portion of the population seeking treatment for AML. Strong growth for AML therapeutics emanates from developed regions, which have higher percentage of population in the 65+ age group, when compared to the developing countries. Developed markets, such as Europe, the US, and Japan, therefore account for a significant portion of the AML therapeutics market, when compared to the developing economies. While the present treatment of AML for elderly patients remain unimpressive, future strategies adopted by drug developers however are geared towards developing novel target based agents.

As stated by the new market research report on Acute Myeloid Leukemia Therapeutics, the US represents the largest and the fastest growing regional market worldwide. After the US, Europe forms the second largest market for AML therapeutics. Vidaza from Celgene Corp., and Ceplene from Epicept are the major AML drugs in Europe.

Given the fact that leukemia is a relatively smaller market (accounting for a meager 1% of the total cancer cases), and the development of drug in this area proving to be less lucrative for developers, there has been a dearth of investments in AML market over the years. However, various regulatory authorities such as the US FDA and European Medicines Agency (EMA) have taken up initiatives to incite interest among pharmaceutical companies to develop innovative therapies targeting AML. One such initiative taken by the regulators is awarding of orphan drug status and fast track designations or both for drugs that are being developed for AML. The move is expected to provide the much needed impetus to the market, as developers can reap benefits on investment faster, with drug hitting the markets at a faster pace and also gaining from the exclusivity benefit of the drug for a longer time period. Furthermore, with high relapse rates, the goal of treatment for AML is centered upon developing therapies, which aid in prolonged remission. Also, Stem cell transplantation, which hitherto has limited therapeutic application in AML market, are expected to become much more refined, thereby improving the scope of stem cell transplantation, particularly for use in low-intensity procedure for the elderly.

Major players in the market include Ambit Biosciences Inc., Aprea AB, Astellas Pharma Inc., Astex Pharmaceuticals Inc., Bio-Path Holdings Inc., BioSante Pharmaceuticals Inc., Celator Pharmaceuticals Inc., Celgene Corp., Clavis Pharma ASA, Cyclacel Pharmaceuticals Inc., EpiCept Corp., Genzyme Corp., Lorus Therapeutics Inc., Novartis AG, Onconova Therapeutics Inc., Sunesis Pharmaceuticals Inc., among others.

The research report titled ?Acute Myeloid Leukemia (AML) Therapeutics: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the AML market, the present treatment options, molecular profile of presently approved drugs, the unmet medical needs, key growth drivers, market challenges, pipeline analysis including late-stage drug pipeline, recent FDA and EMAE approvals, drugs obtaining fast track and orphan drug designations, failed drugs, clinical trials, mergers and acquisitions, other strategic corporate deals, and profiles of major and niche key players globally and across different regions. The report provides annual sales estimates and projections for AML Therapeutics market in US$ Million for the years 2009 through 2017 for the following geographic markets – US, Japan, Europe, and Rest of World.

For more details about this comprehensive market research report, please visit ?

http://www.strategyr.com/Acute_Myeloid_Leukemia_AML_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/







Read More

Global Anxiety Disorders Market to Reach $5.9 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

July 08, 2012     No comments

San Jose, CA (Vocus/PRWEB) April 12, 2011

GIA announces the release of a comprehensive global report on Anxiety Disorders market. The global market for anxiety disorders is forecast to reach $ 5.9 billion by the year 2017. Key factors driving market growth include rising stress levels that are further augmented by the recent financial crisis, increasing incidence and prevalence of anxiety disorders, growing aging population globally, existence of significant unmet needs, and the development of novel therapeutics.

Stress is one of the most significant health issues of the twenty-first century, to the extent of being called a global epidemic. Anxiety is a normal reaction to stress, which helps one deal with tense situations in the office, study harder for an exam, or keep focus on an important speech. In general, it helps one cope. But when anxiety becomes an excessive, irrational dread of everyday situations, it turns into a disabling disorder. Anxiety disorders represent the most commonly occurring mental health condition, affecting individuals of all age groups. In the recent years, the number of people suffering from anxiety disorders increased considerably owing to the global financial crisis that resulted in rising unemployment rates, and increasing stress levels. Ever-increasing aging global population is also one of the factors responsible for the rapid increase in sales of central nervous system drugs. Major types of anxiety disorders with high prevalence include Social Anxiety Disorder, Post-Traumatic Stress Disorder, Generalized Anxiety Disorder, Panic Disorder, and Obsessive-Compulsive Disorder.

Anxiety therapy addresses and eliminates specific factors causing the disorder and inhibits their reoccurrence, thereby helping in restoring and maintaining normal health of the affected individuals. The first line of agents used for the treatment of anxiety includes Selective Serotonin Reuptake Inhibitors such as Lexapro (Escitalopram), Paxil (Paroxetine), Zoloft (Sertraline), and Prozac (Fluoxetine). The other medications prescribed consist of GABA analogues, including new antidepressant Remeron (Mirtazapine); and MAOIs including Parnate (Tranylcypromine) or Nardil (Phenelzine), Lyrica (Pregabalin) or Neurontin (Gabapentin). TCAs, including Imipramine; atypical anti-psychotics including Quetiapine; and Piperazines including hydroxyzine, are also used for the treatment of anxiety. However, these medications are known to cause various side effects and complications.

Despite being the foundation for pharmacological treatment pertaining to anxiety disorders, the response rate of serotonergic-based treatment is more often below the robust level. In addition, though an array of treatment options are available for treating anxiety disorders, about one-third of patients suffering from psychiatric conditions still do not respond to the drugs that are presently available in the market. There exists an ever-increasing need for developing medications that offer a faster onset of action as compared to the presently available drugs. The research projects being undertaken by companies partly focus on the conventional mode of action, such as adjustment of nor-adrenaline and serotonin levels in the brain, and partly on unique and new mechanism. Physicians are looking at novel drugs for the treatment of anxiety disorders.

The existence of Neurokinin (NK) receptor antagonists, along with Corticotrophin Releasing Factor (CRF) antagonists within the anxiety disorders pipeline, drew major interest from key market participants. The NK receptor antagonists are expected to emerge as promising drugs for the treatment of anxiety disorders. Further, the market is expected to witness a transformation, with anti-psychotic drugs expected to change the future landscape of the anxiety disorder drugs market. Manufacturers of antidepressants are expected to enhance their products’ target patient potential, considering the higher co-morbidity between depression and anxiety.

The US represents the largest regional market for anxiety disorder therapeutics worldwide, as stated by the new market research report on Anxiety Disorders. The US registers the highest number of anxiety disorder cases annually. The country incurs a cost of over US$ 42 million per annum for anxiety disorders, which accounts for almost one-third of the overall cost for mental illnesses. About 27% of the European population suffers from brain disorders, with depression being the most prevalent health problem in several EU-Member States. However, Asia-Pacific is forecast to register the fastest growth during the analysis period, registering a compounded annual growth rate of more than 5.0% during 2009-2017.

Major players profiled in the report include AstraZeneca Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan Inc., Neurocrine Biosciences, Inc., Pfizer Inc., Ratiopharm, Sanofi-Aventis, Valeant Pharmaceuticals, Watson Laboratories, among others.

The research report titled ?Anxiety Disorders: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the anxiety disorders therapeutics markets, current market trends, key growth drivers, leading drugs in the market, overview of pipeline drugs, recent product approvals/launches, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for anxiety disorders therapeutics market for the years 2009 through 2017 for the following geographic markets – US, Europe, Asia-Pacific, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Anxiety_Disorders_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

E-mail: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

# # #







Read More
« Older posts
Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv